---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-214871"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:48:54.541234+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atea Pharma Q2 net loss $31.3M; bemnifosbuvir enters late-stage COVID-19 trial

## Summary
- Net loss of $31.3M ($0.38 diluted loss per share) vs net income of $1.5M in Q2 2021; no collaboration revenue.
- Cash and equivalents $684.5M at June 30, 2022, down from $764.4M at Dec 31, 2021.
- Bemnifosbuvir to advance to global late-stage trial for COVID-19 in Q4 2022; primary endpoint hospitalization/death in high-risk patients.
- MORNINGSKY Phase 3 missed primary symptom alleviation endpoint but showed 71% reduction in hospitalization (exploratory p=0.047).
- AT-752 for dengue and HCV combo trial advancing; initial results expected Q4 2022.

## SEC filing metadata
- accession: 0001193125-22-214871
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312522214871/0001193125-22-214871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312522214871/d356253d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-214871
- JSON: https://secwatch.observer/filing/0001193125-22-214871.json
- Plain text: https://secwatch.observer/filing/0001193125-22-214871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.